The Neuro-Oncological Ventral Antigen 2 NOVA2 protein is a major factor regulating neuron specific alternative splicing, previously associated with an acquired neurologic condition, the paraneoplastic opsoclonus-myoclonus ataxia (POMA). We report here six individuals with de novo frameshift variants in the NOVA2 gene affected with a severe neurodevelopmental disorder characterized by intellectual disability (ID), motor and speech delay, autistic features, hypotonia, feeding difficulties, spasticity or ataxic gait and abnormal brain MRI. The six variants lead to the same reading frame, adding a common 133 aa long proline rich C-terminus part instead of the last KH RNA binding domain. We detected fortyone genes differentially spliced after NOVA2 inactivation in human neural cells. The mutant NOVA2 protein shows decreased ability to bind a target RNA, to regulate specific splicing events and to rescue the phenotype of altered retinotectal axonal pathfinding induced by loss of NOVA2 ortholog in zebrafish. Our results suggest a partial loss-of-function mechanism rather than a full heterozygous loss of function, although a specific contribution of the novel C terminal extension cannot be excluded on the basis of the genetic findings.
INTRODUCTION
Many genes that play important roles in the development of the nervous system undergo alternative splicing (AS) to generate protein variants with different functions. The use of alternative mRNA isoforms is a critical process crucial during neuronal development, since specific proteins are required at different time and space. Such mRNA diversity is coordinated by different RNA-binding proteins (RBPs). NOVA (Neuro-Oncological Ventral Antigen) proteins, NOVA1 and NOVA2, are two RBPs involved in neuronal-specific alternative splicing [1] [2] [3] . They have been first described as antigens in patients with a paraneoplastic neurologic syndrome (POMA), a acquired autoimune neurological disorder characterized by ataxia with or without opsoclonus-myoclonus, with or without dementia, encephalopathy and cortical deficits along other symptoms 4, 5 . The two proteins share three similar KH-domains through which they bind directly to YCAY motifs (where Y stands for a pyrimidine) in the messenger RNA (mRNA) sequence [6] [7] [8] . According to the binding location on mRNA, they can either induce exon skipping or exon retention 9 .
Both NOVA1 and NOVA2 are mainly expressed in the central nervous system. However, they show differential expression in specific brain regions in mouse 4 . For instance, NOVA2 is primarily expressed in cortex and hippocampus, whereas NOVA1 is mainly present in midbrain and spinal cord 10, 11 . Both the Nova1 and the Nova2 null mice manifest growth retardation, progressive motor dysfunction and death shortly after birth while corpus callosum agenesis is present only in Nova2 -/mice 2, 11 . This peculiar defect suggested that NOVA1 and NOVA2 are controlling different set of RNA transcripts. As a matter of fact, NOVA2 seems to be mainly associated with a splicing regulation of genes involved in axonal guidance and projection during the development of a mouse cortex (E18.5), as well as genes implicated in cerebellar function or synapse formation 11, 12 . These alternative splicing (AS) events are developmentally regulated between E12.5 and E18.5 in mouse cortex, highlighting an important role of NOVA2 as an axonal pathfinder modifier during cortical development.
Intellectual disability (ID) is a group of neurodevelopmental disorders (NDD) characterized by significant limitations in both intellectual functioning and adaptive behaviour reflected by an intellectual quotient below 70 before the age of 18. It is genetic in origin in a majority of the cases and these genetic anomalies include chromosomal abnormalities, copy number variants, and point mutations or small insertions/deletions (indels) affecting one of the thousands of genes identified so far as causing ID/NDD when mutated 13 . Large-scale sequencing studies combined with international data exchange allow identification of many novel genes. We report here six individuals with frameshift variants in NOVA2 that cluster between sequences encoding the second and the third KH domains. We showed that NOVA2 regulates a series of AS events linked to neurite outgrowth and axonal projections in human neural stem cells (hNScs), and that mutant proteins lose, at least partially, the ability to regulate these splicing events. Finally, we demonstrated that inactivation of NOVA2 ortholog impaired axon outgrowth in vivo using a zebrafish model and that mutant proteins, on the contrary to wild-type NOVA2, failed to rescue this phenotype.
RESULTS

Identification of de novo frameshift variants in NOVA2 leading to expressed truncated proteins sharing the same C-terminal part.
We identified a de novo frameshift variant, c.782del p.(Val261Glyfs135*), in the NOVA2 gene (MIM601991) in a an individual with severe intellectual disability (ID) (Individual 1). We collected five additional unrelated individuals with ID with indel variants in NOVA2, identified by exome sequencing (ES) by different molecular diagnostic laboratories or research centers (Figure 1a-c) . The compilation of these variants resulted from an international collaborative effort partly facilitated by the web-based tool GeneMatcher 14 .
All individuals were initially and a posteriori clinically assessed by at least one expert clinical Frameshift variants in NOVA2 lead to expressed truncated proteins sharing the same Cterminal part.
All six variants are located in the last and largest exon of the gene and lead to frameshifts starting from the same region of the protein (between amino acids 237 and 261).
They are predicted to remove the third KH domain of the protein (KH3, amino acids 406-473), which binds RNA loops composed of the tetranucleotide YCAY 7 . The location of all the variants in the last exon of the gene suggested that the mutant transcripts would escape to nonsense-mediated decay (NMD), but the absence of expression in blood prevents confirmation experiment. All the frameshift variants lead to the same alternative frame and the resulting truncated proteins share a common sequence of 133 novel amino acids (Figure S1-S2). When overexpressed from plasmid in HeLa cells, mutant NOVA2 protein carrying the variant p.Val261Glyfs*135 identified in Individual 1 (Mut1) is normally expressed and localized ( Figure S3 ) with no difference in stability compared to the wild-type protein (cycloheximide treatment, data not shown).
NOVA2 inactivation alters axonal guidance in vivo
We inactivated nova1a, the zebrafish orthologous gene for NOVA2 (Uniprot ID: Q1LYC7)
sharing 78% of sequence identity, using a morpholino (MO). A reduction of the number of axonal tracts formed between optic tecta was observed, as well as a reduction of the tecta size.
We counted a total of 29 inter-tecta axonal tracts in control larva whereas the number of inter-tecta axonal tracts was reduced to 10 with an overall altered brain architecture in morphant larva (Figure 2a-b) . In vivo complementation assay was performed and we observed that 25pg of human WT NOVA2 mRNA, but not 25pg of the human Mut1 NOVA2 mRNA, rescued the MO phenotype. The injection of either the WT or Mut1 NOVA2 mRNA alone did not affect significantly the number of inter-tecta axonal tracts compared to controls.
Individuals carrying de novo frameshift variants in NOVA2 present with ID, autistic features and other Angelman syndrome-like clinical manifestations
The main clinical features of the six individuals are summarized in 
Identification of splicing events regulated by NOVA2 in human neuronal cells
Most of the data concerning splicing target events regulated by NOVA2 have been generated in mice. In order to identify alternative splicing (AS) events regulated by NOVA2 in human neuronal cells, we used human neural stem cells (hNSCs), self-renewal homogeneous precursors of cortical neurons, derived from embryonic stem cells (SA001). hNSCs were treated with NOVA2 siRNA, which led to a reduction of 50% in average (+/-0.09%, n=6) of NOVA2 mRNA without affecting NOVA1 expression (data not shown). Transcriptomic (Figure 3a) . We found that two third of these genes (26/41) have been previously reported as differently spliced in cortex of Nova2 Ko mice, including SGCE, NEO1, DAB1, SLIT2, SORBS1, and others 11 . A significant decrease of the skipping of exon 9 from SGCE (sarcoglycan epsilon) transcripts was observed for instance in hNSCs after NOVA2 inactivation (adj. p=1.02e-5, deltaPsy=0.11) (Figure 3b) . The effects of NOVA2 inactivation on the regulation of this AS event were confirmed in another line of hNSCs (GM01869) (Figure 3c ). Consistent with these results, we were able to identify several NOVA2 target sequences YCAY in the beginning of SGCE intron 9 (Figure 3d ). The SGCE gene encodes the epsilon-sarcoglycan, a transmembrane protein component of the dystrophinglycoprotein complex, connecting the actin cytoskeleton to the extracellular matrix, and is known to be submitted to alternative splicing. It causes myoclonus dystonia when mutated 16 .
Among the other AS events significantly affected by NOVA2 inactivation, we can find for instance a decrease of exon 26 skipping in NEO1 transcripts (adj. p=0.018, deltaPsy=0.02), which was previously described in mice 17 (Figure S5a-b ( Figure S7a-b) . The effects of NOVA2 inactivation on the regulation of these additional AS events were also confirmed in the GM01869 cell line (Figure S5c , S6c, S7c).
Mut1 variant (Val261Glyfs135*) alters NOVA2 ability to bind target sequences and to regulate target alternative splicing (AS) events
Mutant proteins lack the third KH-type domain and we therefore wanted to test their ability to bind RNAs containing the YCAY motif. A gel-shift assays using labeled RNA containing three YCAY sequences showed a significant reduction in RNA binding capacity for NOVA2
Mut1 protein compared to WT NOVA2 (Figure 4a ). We then wanted to test the ability of the mutant protein to regulate AS events normally regulated by NOVA2. In HeLa cells, which do not express NOVA2, we observed for instance that most of the SGCE transcripts contain exon 9 (Figure 4b) . This is consistent with what we observed in hNSCs, where a loss of NOVA2 expression leads to a decrease of exon 9 skipping. The overexpression of WT NOVA2 in HeLa cells leads on the contrary to a significant increase of exon 9 skipping, not observed anymore when Mut1 NOVA2 is overexpressed, demonstrating that the mutant protein has lost its ability to regulate this AS event. We also tested ability of Mut1 NOVA2 to regulate the additional AS events identified in NEO1, SORBS1 or AKAP13. The overexpression of WT NOVA2 leads to a significant increase of the skipping of NEO1 exon 26 and AKAP13 exon 12, and the inclusion of SORBS1 exon 5 (Figure S8) . The complementation assays performed in HeLa cells showed that Mut1 NOVA2 fails to regulate the skipping of SORBS1 exon 5 but has at least partially preserved activity concerning the regulation of NEO1 exon 26 and AKAP13 exon 12 skipping ( Figure S8) . In order to test if the hundred amino acids introduced by the frameshift variants at the C-terminal part of the protein could influence the maintaining of a partial activity of Mut1 NOVA2 protein in the regulation of NEO1 or AKAP13 splicing, we introduced in NOVA2 cDNA a nonsense variant located near to the variants identified in patients, Tyr231*. The resulting truncated protein, which does not contain the hundreds of amino acids added by the frameshift variants, is stably expressed in HeLa cells (Figure S3 ).
On the contrary to Mut1 NOVA2, Tyr231* NOVA2 fails to increase the skipping of exon 26
from NEO1 transcripts and the skipping of exon 12 from AKAP13 transcripts when it is overexpressed in HeLa cells ( Figure S8 ). Coexpression of the WT and Tyr231*, or WT and Mut1 NOVA2 in HeLa cells have a similar effect on AS than the expression of WT alone ( Figure S8 ).
Discussion
We report here a case series of six individuals with severe intellectual disability sharing common autistic features and carrying de novo frameshift variants in the same region of the NOVA2 gene, between two KH RNA-binding domains. This gene encodes an RNA binding protein which is an alternate splicing regulating factor expressed during brain development. We showed that the variant identified in Individual 1 (Mut1 or p.Val261Glyfs135) affects NOVA2 ability to regulate alternative splicing (AS) events and to bind RNA target sequences. All the indel variants cause a shift leading to the same reading frame (frame -1) which results in the addition of a common novel C-terminal part of 133 amino acids from Val261, rich in proline (29.3%) and arginine (12.8%). The alternative frame (frame +1) would have led on the contrary to a more premature stop codon, twenty amino acids downstream of Val261.
To our knowledge, the only case of a specific disorder only caused by such specific distal frameshifts not causing nonsense mediated mRNA decay (NMD) in a single alternate frame resulting in a common long C terminal extension, is the Robinow developmental syndrome (OMIM: 616331 and 616894). This syndrome is characterized by limb and genital anomalies and perturbation of WNT signaling, where in the two orthologous genes implicated, the DLV1 and DLV3 genes, common proline-arginine rich C terminal extensions of 107 aa (DLV1) or 85 aa (DLV3) have been observed in at least 17 and 6 independent patients, respectively, in the absence of any other type of mutations in these two genes 18, 19 . The authors theorized that the mutant proteins would have a dominant-negative or gain of function effect, although partial loss of function related to the loss of C terminal functional domains were also observed. In the case of indel frameshift variants in NOVA2, our functional studies presently support more a loss-of-function effect rather than a dominant negative or gain of function effect. Indeed, no effect was observed when we expressed Mut1 NOVA2 mRNA alone in zebrafish. On the contrary, Mut1 NOVA2 mRNA could not rescue the phenotype of loss of axonal projection observed when NOVA2 is inactivated. The Mut1 protein presents also a partial loss of its splicing regulation activity. Its ability to regulate some AS events is strongly affected in some cases (SGCE or SORBS1) but only mildly or not affected in others We demonstrated that NOVA2, like its rodent counterpart, regulates alternative splicing (AS) of different genes encoding proteins involved in signal transduction and cytoskeleton organization, playing a role in neuronal differentiation and migration. In particular, partial inactivation of NOVA2 leads to mis-regulation of splicing of several transcripts encoding proteins essential for axon outgrowth and pathfinding (NEO1, SLIT2, etc). In vivo, the consequences of axonal projection impairments could be illustrated for instance in mammals by corpus callosum hypoplasia (observed in Individuals 4 and 5) or agenesis (previously identified in mice model 21 ) , but also in zebrafish by the decrease in number of inter-tecta axonal tracts, whose onset involves molecular mechanisms conserved with those of mammals. AS is an essential mechanism aiming at increasing protein diversity and contributes among others to the different critical steps of brain development such as neuronal differentiation, migration, axon guidance, and synaptogenesis. A quarter of the genes identified with AS events mis-regulated when NOVA2 is partially inactivated are known to cause neurodevelopmental or neurological disorders when mutated, highlighting their crucial role during brain development ( Table 2 ). In addition to NOVA2, another gene encoding a protein playing a pivotal role in the regulation of alternative splicing in brain, RBFOX1, also named Ataxin-2-binding protein 1 (A2BP1) or FOX1, is known to be involved in neurodevelopmental disorders. First, its expression was found to be reduced in brains collected postmortem from individuals with ASD leading to alteration of splicing of its predicted targets such as GRIN1 or MEF2C 22 . Moreover, structural variants affecting RBFOX1 have been reported in several patients with ASD, epilepsy and ID [23] [24] [25] .
Mis-regulation of splicing of genes important for brain functioning have also been reported in neurodegenerative diseases, such as Alzheimer disease, fronto-temporal dementia, amyotrophic lateral sclerosis, etc 26 Rolph Pfundt, personal communication). However, the frameshift variants we report in this study are located in a GC-rich internally repetitive region of NOVA2 that is very poorly represented in most exome sequencing data (Figure S9) . Moreover, half of the frameshifts we identified are caused by indels of 20 to 40 bp, that are difficult to detect in standard exome protocols, especially when relatively short read lengths are used (75 bp to 100bp). This study highlights the importance of the regulation of AS events during brain development and how alterations of this regulation might lead to brain dysfunction.
METHODS
Patients and genetic analyses
Individual 1 and biological parents were followed at the Service de Génétique Médicale of Nantes Universitary Hospital, and were enrolled for genetic testing in the laboratory of genetic diagnosis of Strasbourg University Hospital. Targeted sequencing of hundred candidate genes for ID did not reveal pathogenic variants 29 . A family trio-based WES was performed as previously described 30 
NOVA2 plasmids and siRNA
Human cells were transfected with a pcDNA3.1 plasmid containing the sequence of human 
Western blot and immunofluorescence
Four series of HeLa cells were transfected with empty pcDNA3.1 or pcDNA3.1 containing wild-type or mutant (Mut1 and Tyr231*) NOVA2 sequences. To control transfection efficiency, cells were co-transfected using a previously published pcDNA3.1-FLAG-THOC6 constructs. 30 . HeLa cells were lysed in RIPA buffer with protease inhibitor cocktail (Roche) 24h hours after transfection. Proteins were separated after denaturation on a 10% acrylamide gel and transferred onto a PVDF membrane. EGFP-tagged NOVA2 proteins were visualized using an in-house mouse anti-GFP antibody (1:10,000). Their expression levels were normalized using the FLAG staining (FLAG antibody: 1:1,000; F1804, Sigma-Aldrich, Saint-Louis, MO, USA).
RNA sequencing
Experiments were performed in duplicate from two independent series of hNSCs were adjusted for multiple testing with the Benjamini and Hochberg method 39 . LeafCutter was used to identify alternative splicing (AS) events between NOVA2 inactivation and other conditions 40 . Genes with AS events were analyzed using the Database for Annotation, Visualization and Integrated Discovery (DAVID 6.7). Biological processes and molecular functions of Gene Ontology Consortium (GO) were used for the functional annotations.
Confirmation of alternative splicing (AS) events identified by RNASeq
GM01869 hNSCs were used to validate results obtained by RNA-Seq in the SA001 line. Cell were treated with tranfecting agent, scramble or NOVA2 siRNA as described for SA001 (each condition in triplicates). For splicing analyses in HeLa cells, 6-well plates of cells were transfected with 2µg of empty or NOVA2 pcDNA3.1 plasmids alone or combined (three to four series of independent experiments were analyzed). mRNA was extracted 24 hours after siRNA transfection using using the RNeasy mini kit (Qiagen, Valencia, CA, USA). 500ng of total RNA was reverse transcribed into cDNA using random hexamers and SuperScript IV reverse transcriptase according to manufacturer's recommendation. PCR was performed (16 cycles of touch-down 70°-54° followed by 8 to 21 cycles at 59° depending of the mRNA), using the following primers NEO1_E25_F 5'-GGAAGGCGAGGAATGAGACCAAAA-3'
and NEO1_E27_R 
Zebrafish experiments
Zebrafish (Danio rerio) were raised and maintained as previously described 41 . We injected Brown-Forsythe and Welch's ANOVA with Holm-Sidak's multiple comparisons *** p<0.001, **p<0.01, * p<0.05, ns: non-significant.
